Biotech startups that raised Series D or later in California, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Circle Pharma | South San Francisco | Series E | $92.5M | 2026-09-16 |
| Craif | Irvine | Series D | $24.4M | 2026-08-18 |
| Lycia Therapeutics | South San Francisco | Series D | $75.0M | 2026-06-25 |
| Element Biosciences | San Diego | Series E | $277.0M | 2026-06-09 |
| Numerion Labs | San Francisco | Series D | $19.8M | 2026-03-19 |
| Angitia Biopharmaceuticals | Westlake Village | Series D | $130.0M | 2026-02-05 |
| Arthrosi Therapeutics | San Diego | Series E | $153.0M | 2025-06-23 |
| Clear Labs | San Carlos | Series D | $30.0M | 2025-01-13 |
8 rows of the CSV in 5 of its 18 columns.
- The 111 biotech startups in California, United States whose last round is Series D or later have raised $20.7B in total.
- 10 of them closed their most recent round in the last 12 months, $1.3B combined.
- The largest of those rounds is Element Biosciences' $277.0M Series E, dated June 2026.
- The most recent is Quanta Therapeutics' $50.7M Series D on 24 October 2026.
- Y Combinator is an investor in 3 of them, more than any other fund.
- Health care is the most common other sector, with 96 companies (86%).
- 1% were founded in 2020 or later; the median founding year is 2006.
- The most common team size is 11 to 50 employees (32% of companies with a recorded size).
- 3 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
16 of 111| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Circle Pharma | Circle Pharma develops bioavailable macrocyclic peptide therapeutics that target protein-protein interactions. | Biotech | South San Francisco | Series E | $92.5M | 2026-09-16 | $300.0M | Mission BioCapital, Pfizer, The Column Group +1 | 11 to 50 | 2012 |
| Craif | Craif develops a cancer diagnosis algorithm using microRNA data and machine learning. | Artificial intelligence | Irvine | Series D | $24.4M | 2026-08-18 | $68.7M | Global Brain Corporation, VentureOut, ANRI +1 | 51 to 100 | 2018 |
| Lycia Therapeutics | Lycia Therapeutics develops technology using lysosome-targeting chimeras to degrade disease-causing proteins. | Biotech | South San Francisco | Series D | $75.0M | 2026-06-25 | $301.6M | Franklin Templeton, Alexandria Venture Investments, Invus +1 | 11 to 50 | 2019 |
| Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | San Diego | Series E | $277.0M | 2026-06-09 | $678.0M | RA Capital Management, Fidelity, Wellington Management +2 | 251 to 500 | 2017 |
| Numerion Labs | Numerion Labs develops artificial intelligence systems for drug discovery using deep learning algorithms. | Artificial intelligence | San Francisco | Series D | $19.8M | 2026-03-19 | $241.4M | Y Combinator, Khosla Ventures, Creative Destruction Lab +1 | 11 to 50 | 2012 |
| Angitia Biopharmaceuticals | Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases. | Biotech | Westlake Village | Series D | $130.0M | 2026-02-05 | $406.0M | Legend Capital, OrbiMed, Oriza Holdings +1 | 51 to 100 | 2018 |
| Arthrosi Therapeutics | Arthrosi Therapeutics develops pharmaceutical treatments through clinical research and drug development programs. | Biotech | San Diego | Series E | $153.0M | 2025-06-23 | $277.4M | Viva BioInnovator, Xiamen Changrong Investment Management, Viva Ventures Biotech Fund | 11 to 50 | 2018 |
| Clear Labs | Clear Labs is a biotechnology firm that uses a genomics system to simplify diagnostics. | Artificial intelligence | San Carlos | Series D | $30.0M | 2025-01-13 | $156.5M | Plug and Play, Alumni Ventures, Khosla Ventures +1 | 51 to 100 | 2014 |
| Moximed | Moximed develops therapies for patients with knee osteoarthritis. | Biotech | Hayward | Series D | $61.0M | 2024-08-13 | $244.2M | New Enterprise Associates, Vertex Ventures, Cormorant Asset Management +1 | 11 to 50 | 2006 |
| Truvian Sciences | Truvian Sciences develops an automated benchtop system for lab-accurate blood testing. | Biotech | San Diego | Series D | $74.0M | 2024-07-17 | $208.1M | General Catalyst, GreatPoint Ventures, Tao Capital Partners +2 | 101 to 250 | 2015 |
| BillionToOne Unicorn | BillionToOne offers genetic testing that detects disease through precision diagnostics. | Biotech | Menlo Park | Series D | $130.0M | 2024-06-21 | $425.9M | Y Combinator, 500 Global, UpHonest Capital +1 | 501 to 1,000 | 2016 |
| Perfect Day Unicorn | Perfect Day produces dairy proteins that are nutritionally identical to proteins from cow's milk. | Biotech | Berkeley | Series E | $90.0M | 2024-01-05 | $801.5M | SOSV, K5 Global, Temasek +2 | 101 to 250 | 2014 |
| DNAnexus | DNAnexus provides a cloud platform and network for scientific collaboration and research. | Biotech | Mountain View | Series H | $200.0M | 2022-03-08 | $472.6M | Google Ventures, First Round Capital, Microsoft | 101 to 250 | 2009 |
| Synthego | Synthego provides genome engineering services and CRISPR tools for life science research. | Artificial intelligence | Redwood City | Series E | $200.0M | 2022-02-17 | $459.7M | Intel Capital, Founders Fund, Menlo Ventures +2 | 101 to 250 | 2012 |
| Zymergen | Zymergen is a biotechnology company that applies machine learning, big data and artificial intelligence. | Artificial intelligence | Emeryville | Series D | $300.0M | 2020-09-08 | $974.1M | Goldman Sachs, DCVC, SoftBank +2 | 501 to 1,000 | 2013 |
| Siperian | Siperian provides model-driven software that delivers mobile management solutions for businesses. | Biotech | Foster City | Series E | $25.0M | 2008-01-22 | $50.2M | Blumberg Capital, Brightspark Ventures, Investor Growth Capital Limited +2 | 1,001 to 5,000 | 2000 |
Table 1. Biotech startups that raised Series D or later in California, United States: the 16 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 111.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | San Diego | Series E | $277.0M | 2026-06-09 | $678.0M | RA Capital Management, Fidelity, Wellington Management +2 | 251 to 500 | 2017 |
| 2 | Angitia Biopharmaceuticals | Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases. | Biotech | Westlake Village | Series D | $130.0M | 2026-02-05 | $406.0M | Legend Capital, OrbiMed, Oriza Holdings +1 | 51 to 100 | 2018 |
| 3 | Circle Pharma | Circle Pharma develops bioavailable macrocyclic peptide therapeutics that target protein-protein interactions. | Biotech | South San Francisco | Series E | $92.5M | 2026-09-16 | $300.0M | Mission BioCapital, Pfizer, The Column Group +1 | 11 to 50 | 2012 |
| 4 | Lycia Therapeutics | Lycia Therapeutics develops technology using lysosome-targeting chimeras to degrade disease-causing proteins. | Biotech | South San Francisco | Series D | $75.0M | 2026-06-25 | $301.6M | Franklin Templeton, Alexandria Venture Investments, Invus +1 | 11 to 50 | 2019 |
| 5 | Craif | Craif develops a cancer diagnosis algorithm using microRNA data and machine learning. | Artificial intelligence | Irvine | Series D | $24.4M | 2026-08-18 | $68.7M | Global Brain Corporation, VentureOut, ANRI +1 | 51 to 100 | 2018 |
| 6 | Numerion Labs | Numerion Labs develops artificial intelligence systems for drug discovery using deep learning algorithms. | Artificial intelligence | San Francisco | Series D | $19.8M | 2026-03-19 | $241.4M | Y Combinator, Khosla Ventures, Creative Destruction Lab +1 | 11 to 50 | 2012 |
Table 2. Biotech startups that raised Series D or later in California, United States: the 6 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Y Combinator | Startup accelerator | Mountain View, United States | 3 | 3% | 1 | Numerion Labs |
| 2 | Wellington Management | Private equity firm | Boston, United States | 2 | 2% | 1 | Element Biosciences |
| 3 | RA Capital Management | Startup incubator | Boston, United States | 2 | 2% | 1 | Element Biosciences |
| 4 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 2 | 2% | 1 | Numerion Labs |
| 5 | OrbiMed | Private equity firm | New York, United States | 2 | 2% | 1 | Angitia Biopharmaceuticals |
| 6 | Menlo Ventures | Venture capital firm | Menlo Park, United States | 2 | 2% | ||
| 7 | Baillie Gifford | Private equity firm | Edinburgh, United Kingdom | 2 | 2% | ||
| 8 | Intel Capital | Corporate venture arm | Santa Clara, United States | 2 | 2% | ||
| 9 | Qualcomm Ventures | Corporate venture arm | San Diego, United States | 2 | 2% | ||
| 10 | Pfizer | Corporate venture arm | New York, United States | 1 | 1% | 1 | Circle Pharma |
| 11 | Mission BioCapital | Venture capital firm | Cambridge, United States | 1 | 1% | 1 | Circle Pharma |
| 12 | Nextech Invest | Venture capital firm | Zürich, Switzerland | 1 | 1% | 1 | Circle Pharma |
| 13 | The Column Group | Venture capital firm | San Francisco, United States | 1 | 1% | 1 | Circle Pharma |
| 14 | VentureOut | Startup accelerator | New York, United States | 1 | 1% | 1 | Craif |
| 15 | Global Brain Corporation | Venture capital firm | Tokyo, Japan | 1 | 1% | 1 | Craif |
Table 3. Biotech startups that raised Series D or later in California, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 96 | 86% | $16.8B |
| Software | 11 | 10% | $3.0B |
| Artificial intelligence | 7 | 6% | $2.3B |
| Hardware | 5 | 5% | $1.3B |
| Energy | 2 | 2% | $228.7M |
| Cybersecurity | 1 | 1% | $188.7M |
| Fintech | 1 | 1% | $72.6M |
Table 4. Biotech startups that raised Series D or later in California, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series D+ | 111 | 100% | $43.7M |
Table 5. Biotech startups that raised Series D or later in California, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Diego | 18 | 16% |
| South San Francisco | 11 | 10% |
| Redwood City | 9 | 8% |
| San Francisco | 7 | 6% |
| Santa Clara | 5 | 5% |
| Mountain View | 5 | 5% |
| Hayward | 4 | 4% |
| Berkeley | 4 | 4% |
| Menlo Park | 3 | 3% |
| La Jolla | 3 | 3% |
| Fremont | 3 | 3% |
| Sunnyvale | 3 | 3% |
Table 6. Biotech startups that raised Series D or later in California, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 1 | 10% | $50.7M |
| September 2026 | 2 | 20% | $367.5M |
| August 2026 | 1 | 10% | $24.4M |
| June 2026 | 2 | 20% | $352.0M |
| May 2026 | 1 | 10% | $52.0M |
| March 2026 | 1 | 10% | $19.8M |
| February 2026 | 1 | 10% | $130.0M |
| January 2026 | 1 | 10% | $257.0M |
Table 7. Biotech startups that raised Series D or later in California, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 10 | 9% | $1.3B |
| 2025 | 8 | 7% | $1.1B |
| 2024 | 7 | 6% | $487.3M |
| 2023 | 5 | 5% | $327.0M |
| 2022 | 3 | 3% | $560.0M |
| 2021 | 8 | 7% | $849.0M |
Table 8. Biotech startups that raised Series D or later in California, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 1 | 1% |
| 2015 to 2019 | 20 | 18% |
| 2010 to 2014 | 17 | 15% |
| Before 2010 | 72 | 65% |
Table 9. Biotech startups that raised Series D or later in California, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 10 | 9% |
| 11 to 50 | 35 | 32% |
| 51 to 100 | 35 | 32% |
| 101 to 250 | 12 | 11% |
| 251 to 500 | 7 | 6% |
| 501 to 1,000 | 5 | 5% |
| 1,001 to 5,000 | 3 | 3% |
| 5,001 to 10,000 | 1 | 1% |
| 10,001 or more | 1 | 1% |
Table 10. Biotech startups that raised Series D or later in California, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series D or later and its headquarters is in California, United States. On 16 November 2026 that is 111 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 16 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 111 rows: 12 have no round amount, 0 no city and 9 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in California, United States whose last round is Series D or later are on the list?
- 111, in the file dated 16 November 2026. 10 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 111 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.